Annolyse
BriefingsCompaniesInsightsPrinciplesCompareWatchlist

Explore

  • Briefings
  • Companies
  • Insights
  • Compare

Resources

  • Search
  • Methodology
  • Developers

© 2026 Annolyse. Analytical briefings for NZX company announcements.

Table of contents

  1. What changed
  2. What matters
  3. Expectations
  4. Quality of result
  5. Unresolved
  6. Key metrics
  7. Segment breakdown
  8. Analytical metrics
  9. Metric context
  10. Reference material
←Back to briefings
Oceania Healthcare (OCA) / HY23

OCA swings to $32.5m pre-tax loss as net debt jumps to $548m

Revenue grew 52% but earnings flipped into loss, operating cash halved, and capex-driven borrowing lifted leverage sharply.

Release date
7 November 2022
Published
22 April 2026
Table of Contents⌄
  1. What changed
  2. What matters
  3. Expectations
  4. Quality of result
  5. Unresolved
  6. Key metrics
  7. Segment breakdown
  8. Analytical metrics
  9. Metric context
  10. Reference material

What changed

Revenue rose 52.1% to $173.3m, but the P&L swung materially negative: profit before tax moved from a $33.5m profit to a $32.5m loss, and net profit after tax went from $36.9m to a $24.1m loss. Operating cash inflow nearly halved to $23.7m from $52.5m. Gross borrowings rose 61.5% to $566.3m, taking net debt to roughly $548.1m from $333.9m. Total assets expanded to $2.47bn and equity to $1.05bn. The interim dividend was cut 40.5% to 1.25cps from 2.10cps. Segment mix shifted toward retirement, which rose to about 30% of revenue from 17%, while care's share fell from 82% to 70%.

What matters

  • Earnings quality flipped, not just softened. PBT fell 197.2% versus a 165.3% fall in NPAT; the gap reflects an $8.4m current-period tax benefit that cushioned the reported loss. PBT is the cleaner read and it is decisively negative. Return on equity went from +4.0% to -2.5%.
  • Balance sheet is the direction of travel. Capex stayed very heavy at $113.3m against materially weaker operating cash, so pre-lease free cash flow deteriorated to -$89.6m from -$63.1m. The gap was funded by borrowing: net debt climbed roughly $214m year-on-year. The equity base grew, but leverage is clearly weakening.
  • Dividend cut corroborates the cash story. A 40.5% DPS cut alongside negative pre-lease FCF signals management is preserving cash rather than sustaining the prior distribution level through debt.

Expectations

No quantitative guidance, forward-work balance, or stated targets were disclosed in the supplied material. HY22 revenue was roughly evenly split across FY22 (HY22 was 49.3% of full-year revenue), while HY22 NPAT was more first-half weighted (60.4% of full-year). Current half-year revenue annualises to $346.5m versus FY22 revenue of $231.1m, but with the current half in loss and prior full-year earnings heavily reliant on first-half contribution, revenue annualisation does not translate into an earnings read. The release supports a scaling-up top-line narrative; it does not support any directional statement on full-year profitability.

Quality of result

Low durability on the earnings line. The reported NPAT loss is flattered by an $8.4m tax benefit, so the underlying operating deterioration is larger than the headline. Operating cash conversion deteriorated materially — OCF fell 54.8% while revenue grew 52.1%. Cash at bank rose only $1.5m year-on-year despite $23.7m of operating inflows, because investing outflows remained very large and were effectively funded by a ~$215m increase in gross borrowings. Segment-level profit for the current half was not disclosed, and underlying EBITDA / underlying NPAT reconciliations referenced in prior-period commentary were not provided this time, limiting transparency on how much of the swing is non-cash fair-value movement versus cash operating margin compression.

Unresolved

  • What drove the pre-tax swing of roughly $66m — fair-value/revaluation movements on investment property, interest cost on the larger debt stack, care-segment operating margin, or a mix?
  • What is underlying EBITDA for HY23, and how does it reconcile to the statutory loss? No current-period non-GAAP reconciliation was supplied.
  • What is the forward sales/settlement pipeline, and does it support continued capex at ~$113m per half?
  • Are there debt covenants or headroom constraints given net debt is now $548.1m with OCF running at $23.7m per half?
  • What is the capital-allocation plan if pre-lease FCF remains deeply negative — further dividend resets, equity, or asset sales?

This briefing cannot assess underlying (non-GAAP) profitability, segment-level margins for the current period, or covenant headroom, because those disclosures were not provided in the supplied extraction.

Key metrics

← Swipe to view more
Key metrics table for Oceania Healthcare HY23
Metric HY23 HY22 Change
Revenue $173.3m $113.9m +52.1% ↑
Net profit after tax −$24.1m $36.9m -165.3% ↓
Net cash inflow from operating activities $23.7m $52.5m -54.8% ↓
Interim dividend per share 1.3c 2.1c -40.5% ↓
Profit before tax −$32.5m $33.5m -197.2% ↓
Total assets $2.5b $2.1b +19.8% ↑

Segment breakdown

← Swipe to view more
Segment breakdown table for Oceania Healthcare HY23
Segment Current revenue Prior revenue Current result Mix shift
Care $121m $93.3m — -12.1pp
Retirement $52.3m $19.7m — +12.9pp
Other — $0.86m — n/a

Analytical metrics

← Swipe to view more
Analytical metrics table for Oceania Healthcare HY23
Metric HY23 HY22 Context
Effective tax rate n/m (loss period) -10.4% current loss period
FCF pre-lease −$89.6m −$63.1m −$26.5m
FCF / NPAT 371.5% -170.9% complementary conversion metric
Capex % revenue 65.4% 101.5% —
Capex −$113.3m −$115.6m +$2.3m
Debtor days 11.5 — —
Trade debtors $11m — —
Net debt $548.1m $333.9m +$214.1m
Gross borrowings $566.3m $350.7m +$215.6m
ROE (annualised) -2.5% 4.0% Weakening
HY22 share of FY22 revenue 49.3% — Other half was 50.7%
HY22 share of FY22 NPAT 60.4% — Other half was 39.6%

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.

Source-backed analysis from the filing set attached to this briefing.

Metric context

Trajectory before this result

A compact view of the company's recent revenue and margin path, derived from the same metrics history that powers the company page.

OCA revenue trajectory

Revenue context before the current result.

← Swipe to view more
OCA revenue trajectory preview table
PeriodOCA
HY26$131.6m
FY25$260.6m
HY25$132.6m
FY24$265.5m
HY24$131.6m
FY23$247.2m

OCA EBITDA margin

Earnings margin across covered periods.

← Swipe to view more
OCA EBITDA margin preview table
PeriodOCA
HY2631.5%
FY25n/a
HY2529.1%
FY2431.1%
HY2428.6%
FY2332.4%

Appendix

Reference material

Company materials considered in this briefing.

Current period

Notice of Half Year Result Announcement

HY23 / financial report↗

Prior comparable period

Interim Report

HY22 / financial report↗

Media Release

HY22 / media release↗

Results Announcement

HY22 / results announcement↗

Full-year context

Annual Report

FY22 / financial report↗

Related insight

See how earnings quality compares across covered companies

→

Email updates

Want briefings like this for the next reporting season?

Get the next Annolyse briefing by email when it is published.

OCA revenue trajectory

Revenue context before the current result.

OCA EBITDA margin

Earnings margin across covered periods.